Hana Pharm Co., Ltd.

As of June 30, 2026, Hana Pharm Co., Ltd. carries a market capitalization of 155.61B, placing it among publicly traded companies globally. Its enterprise value stands at 208.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hana Pharm Co., Ltd.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, Hana Pharm Co., Ltd. has 17.72M shares outstanding.

As of June 30, 2026, Hana Pharm Co., Ltd. trades at a trailing price-to-earnings ratio of 8.80. The price-to-sales ratio is 0.62, and the price-to-book ratio stands at 0.47.

As of June 30, 2026, Hana Pharm Co., Ltd. trades at an EV/EBITDA multiple of 5.01 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 7.30 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 208.44B versus a market cap of 155.61B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hana Pharm Co., Ltd. maintains a current ratio of 1.96, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Hana Pharm Co., Ltd. posted a return on equity (ROE) of 5.44, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.72 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.18, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.68, useful for judging operating efficiency across full business cycles. The company generates approximately 346.62M in revenue per employee across its workforce of 713.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.62 indicates how many times Hana Pharm Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Hana Pharm Co., Ltd. recorded 10.55B in income tax expense. That works out to an effective tax rate of 37.66, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 28.02B, leaving 17.46B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Hana Pharm Co., Ltd.'s stock has declined approximately 30.24% over the past 52 weeks. The 50-day moving average sits at 8,428.60, while the 200-day moving average is 9,298.15.

Over the twelve months ended June 30, 2026, Hana Pharm Co., Ltd. generated 247.31B in revenue and converted that into 17.46B in net income, yielding earnings per share of 996.41. EBITDA reached 41.60B, while operating income came in at 28.56B.

As of June 30, 2026, Hana Pharm Co., Ltd. holds 17.28B in cash and equivalents against 70.12B in total debt, resulting in a net debt position of 53.94B. Total book value stands at 331.75B, with working capital of 61.65B providing operational flexibility.

Hana Pharm Co., Ltd. produced 16.43B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -71.44B in capital expenditures, free cash flow totaled -55.01B - equivalent to -3,143.06 per share.

Over the twelve months ended June 30, 2026, Hana Pharm Co., Ltd. posted a gross margin of 60.72, reflecting its pricing power and cost economics. The operating margin of 11.55 and net profit margin of 7.06 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Hana Pharm Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -35.75: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -20.58, meaning Hana Pharm Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Hana Pharm Co., Ltd.'s most recent stock split took place on April 28, 2021 with a 10:11 split ratio.

As of June 30, 2026, Hana Pharm Co., Ltd. has an Altman Z-Score of 2.43, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.